Eli Lilly
Eli Lilly
$3,000.00
PharmaVitae explores Eli Lilly’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
PharmaVitae explores Eli Lilly’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
Snapshot
- Overview – Eli Lilly’s prescription pharmaceutical business is reversing recent declines and will grow out to 2027.
- Key themes – [1] Diabetes growth will be restricted by external GLP-1 competition and insulin price caps [2] Eli Lilly’s CNS portfolio will be the company’s greatest growth driver [3] Olumiant’s regulatory issues will hamper growth out to 2027.
- Q2 2018 – Eli Lilly’s launch drugs drive strong growth in the quarter.
- Out to 2022 – Topline revenue growth of $4.3bn out to 2022 as the company successfully weathers generic pressures to Humalog, Alimta, and Cialis.
- Out to 2027 – $6.5bn growth owing to strong launch portfolio.
- Pipeline – Eli Lilly’s launch portfolio includes Verzenio, Olumiant, Emgality, and lasmiditan.
- Lifecycle – The company’s launch portfolio will offset declines from the core franchise.
- Events – Generic competition for Cialis will begin to negatively impact sales in H2 2018; launch of Emgality in Q3 2018.
Analysis structure
Explore and visualize revenue dynamics in Eli Lilly’s portfolio out to 2027 using 10-year in-house sales forecasts segmented by the following sections.
Quarterly review
- What were the major highlights from Eli Lilly’s latest earnings calls and quarterly performance?
Strategy analysis
- How is Eli Lilly strategically poised out to 2027?
- What are Eli Lilly’s key strengths, weaknesses, opportunities, and threats?
- What are Eli Lilly’s key catalysts during the current year?
Portfolio analysis
- Why will specific therapy areas experience the largest growth and decline?
- What are the detailed competitive dynamics at play in Eli Lilly’s important therapeutic markets?
- How is Eli Lilly adapting strategically to internal and external headwinds in preceding quarters?
Facts and figures
- What is Eli Lilly’s forecasted sales performance out to 2027?
- What is the revenue trajectory of Eli Lilly’s current top 10 products out to 2027?
- Which therapy areas will experience the largest growth and decline?
- What are the portfolio weightings of Eli Lilly based on the lifecycle of its products?
Table of Contents
6 OVERVIEW
6 Snapshot
6 Analysis structure
8 Q2 2018 REVIEW
8 Eli Lilly’s launch drugs drive strong growth in the quarter
10 Eli Lilly’s launch products have mixed prospects
10 Upcoming catalysts
11 Bibliography
12 Q1 2018 REVIEW
12 Regulatory issues for baricitinib overshadow strong growth in the quarter
13 Pipeline update
16 Q4 2017 REVIEW
16 Strong sales in Eli Lilly’s launch portfolio offset headwinds in diabetes
17 Diabetes market dynamics
17 Key catalysts in 2018
20 Bibliography
21 Q3 2017 REVIEW
21 What were the highlights of Eli Lilly’s Q4 2017 earnings call?
21 Strategic review of Elanco Animal Health
21 Looking to 2018
21 Financials
22 Streamlining operations
22 Regulatory
22 Clinical data update
22 Bibliography
24 STRATEGY ANALYSIS
24 Background
24 Internal R&D
24 Eli Lilly’s new oncology strategy
24 Acquisition strategy
25 Eli Lilly’s SWOT analysis
26 Eli Lilly’s key events and catalysts
26 Bibliography
28 PORTFOLIO ANALYSIS
30 Q2 2018
31 Q1 2018
32 Q4 2017
35 Q3 2017
41 FACTS AND FIGURES
41 Eli Lilly’s prescription pharma sales outlook
41 Eli Lilly’s regional pharma sales outlook
43 Eli Lilly’s therapy area dynamics
51 Eli Lilly’s growth drivers and resistors
54 Eli Lilly’s lifecycle analysis
56 Eli Lilly’s pipeline analysis
58 Eli Lilly’s M&A strategy and history
LIST OF FIGURES
41 Figure 1: Eli Lilly’s prescription pharmaceutical sales ($m) and growth rate (%), 2014–27
43 Figure 2: Eli Lilly’s therapy area dynamics, 2017–27
54 Figure 3: Eli Lilly’s launch/core/expiry portfolio configuration, 2017–27
56 Figure 4: Eli Lilly’s pipeline overview
LIST OF TABLES
9 Table 1: Eli Lilly product sales ($m), Q2 2018 and Q2 2017
14 Table 2: Eli Lilly key product sales ($m), Q1 2018 and Q1 2017
19 Table 3: Eli Lilly product sales ($m), full-year 2017 and Q4 2017
29 Table 4: Eli Lilly’s sales by therapy area ($m), 2017–27
42 Table 5: Eli Lilly’s prescription pharmaceutical sales by region ($m), 2017–27
44 Table 6: Eli Lilly’s sales by therapy area ($m), 2017–27
46 Table 7: Eli Lilly’s metabolic portfolio sales, by product ($m), 2017–27
48 Table 8: Eli Lilly’s oncology portfolio sales, by product ($m), 2017–27
49 Table 9: Eli Lilly’s genitourinary portfolio sales, by product ($m), 2017–27
50 Table 10: Eli Lilly’s central nervous system portfolio sales, by product ($m), 2017–27
51 Table 11: Eli Lilly’s immunology and inflammation portfolio sales, by product ($m), 2017–27
52 Table 12: Eli Lilly’s key products, 2017–27
55 Table 13: Eli Lilly’s sales by launch, core, and expiry portfolio ($m), 2017–27
57 Table 14: Eli Lilly’s launch portfolio sales, by product ($m), 2017–27
59 Table 15: Eli Lilly’s key merger and acquisition deals, 2004–18
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the